REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – An integrated analysis of BG-12 trials indicates that there is a low incidence of serious adverse events during treatment although flushing and gastrointestinal effects are common (Phillips et al. AAN 2013; abstract S30.003).
Latest News
Natalizumab update: anti-JCV Ab testing and PML risk
March 22, 2013REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – A second-generation STRATIFY assay produces a lower false-negative rate and less variability in serostatus results compared to the original STRATIFY-1 test, according to the latest data.
Brain atrophy reduced with fingolimod
March 22, 2013REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – An analysis of three phase III studies reports a significant reduction in the rate of brain atrophy during treatment with fingolimod (Cohen et al. AAN 2013; abstract S51.006). Brain volume was measured using SIENA/SIENAX. Data were analysed for the two-year placebo-controlled FREEDOMS and FREEDOMS II trials, and the one-year TRANSFORMS trial comparing fingolimod to interferon-beta-1a IM.
Pregnancies may slow disability progression
March 21, 2013REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – It is well established that the frequency of MS relapses declines during pregnancy, then returns to pre-pregnancy levels during the postpartum period. Recent studies suggest that parity may also have an impact on long-term disability.